Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Monday session in green amid volatile trading. The shares closed up +0.56 points or 2.00% at $28.62 with 18.09 million shares getting traded. Post opening the session at $27.81, the shares hit an intraday low of $27.35 and an intraday high of $28.93 and the price vacillated in this range throughout the day. The company has a market cap of $9.15 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
On Sept. 6, 2016 Valeant Pharmaceuticals International, Inc. (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.
“We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC,” said Joseph C. Papa, Chief Executive Officer of Valeant. “This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant’s continued commitment to delivering innovative products that improve people’s lives.”
Shares of HeartWare International Inc (NASDAQ:HTWR) ended Monday session at $57.98 with 762.00 shares getting traded. The company has a market cap of $1.02 billion and the numbers of outstanding shares have been calculated to be 17.56 million shares.
HeartWare International Inc (HTWR) on July 28, 2016 announced total revenue of $68.7 million for the quarter ended June 30, 2016, compared to $73.6 million for the same period in 2015 and $55.1 million for the first quarter of 2016. Total revenue decreased approximately 7% year-over-year, which is primarily attributable to the third quarter 2015 completion of enrollment of the company’s ENDURANCE2 Destination Therapy (DT) clinical trial, which contributed approximately $5 million to revenue in the second quarter of 2015.
During the second quarter, a total of 715 HeartWare HVAD® Systems were sold globally, representing a sequential-quarter increase of 24% from 578 units sold in the first quarter of 2016. A total of 371 units were sold in the U.S. during the second quarter, representing an increase of 26% on a sequential-quarter basis, primarily due to a rebound in the overall bridge-to-transplant market. A total of 344 units were sold internationally during the second quarter of 2016, representing an increase of 22% on a sequential-quarter basis, primarily due to increased sales in most European markets, with the exception of a slight unit decrease in Germany.